Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)
KCT0005256Phase 2Recruiting
- Sponsor
- AngioLab, Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALS-L1023 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AngioLab, Inc.. Started Dec 2019; status: recruiting.
02
Drugs
ALS-L1023
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on KCT0005256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005256.